Antiperinuclear activity in lung carcinoma patients

Area of Science:

• Immunology
• Oncology
• Biomarker Discovery

Background:

• Antiperinuclear factor (APF) is a serum factor potentially related to rheumatoid factors.
• APF's specific target is suggested to be keratohyaline granules.
• The diagnostic utility of APF in cancer, particularly lung cancer, remains to be fully elucidated.

Purpose of the Study:

• To investigate the presence and diagnostic significance of antiperinuclear factor (APF) in patients with lung cancer.
• To compare APF prevalence in lung cancer patients versus normal controls.
• To explore the correlation between APF levels and clinicopathological features of lung cancer, including tumor dissemination and histopathological type.

Main Methods:

• Detection of antiperinuclear factor (APF) in serum samples from patients diagnosed with primary or metastatic lung cancer.
• Comparison of APF detection rates between the lung cancer cohort and a sex- and age-matched control group of normal individuals.
• Statistical analysis to assess the correlation between APF frequency and titer with tumor dissemination and histopathological classification.

Main Results:

• Antiperinuclear factor (APF) was detected in 50.6% of primary and 58.3% of metastatic lung cancer patients.
• APF was present in only 12.6% of normal controls, indicating a significantly higher prevalence in lung cancer patients.
• A positive correlation was observed between APF frequency and titer with tumor dissemination, but no association was found with histopathological type.

Conclusions:

• Antiperinuclear factor (APF) shows potential as a specific serum biomarker for detecting lung cancer.
• The elevated presence and titer of APF in lung cancer patients, particularly with tumor spread, warrant further investigation.
• APF may serve as a valuable indicator of tumor dissemination in lung cancer patients.